Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM.

Risk Anal. 2013 Apr;33(4):606-46. doi: 10.1111/risa.12031. Epub 2013 Mar 28. Review.

PMID:
23550968
2.

Expert review on poliovirus immunity and transmission.

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM.

Risk Anal. 2013 Apr;33(4):544-605. doi: 10.1111/j.1539-6924.2012.01864.x. Epub 2012 Jul 15. Review.

PMID:
22804479
3.

Anomalous observations on IPV and OPV vaccination.

John TJ.

Dev Biol (Basel). 2001;105:197-208.

PMID:
11763328
4.

Modeling population immunity to support efforts to end the transmission of live polioviruses.

Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL.

Risk Anal. 2013 Apr;33(4):647-63. doi: 10.1111/j.1539-6924.2012.01891.x. Epub 2012 Sep 17.

PMID:
22985171
5.

Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.

Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM.

Risk Anal. 2013 Apr;33(4):703-49. doi: 10.1111/risa.12044. Epub 2013 Mar 22.

PMID:
23521018
6.

Interrupting the transmission of wild polioviruses with vaccines: immunological considerations.

Ghendon Y, Robertson SE.

Bull World Health Organ. 1994;72(6):973-83. Review.

7.
8.
9.

Eradication of poliomyelitis in the United States.

Nathanson N.

Rev Infect Dis. 1982 Sep-Oct;4(5):940-50.

PMID:
7146731
10.

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM.

Risk Anal. 2013 Apr;33(4):680-702. doi: 10.1111/risa.12022. Epub 2013 Mar 7.

PMID:
23470192
11.

Waning intestinal immunity after vaccination with oral poliovirus vaccines in India.

Grassly NC, Jafari H, Bahl S, Sethi R, Deshpande JM, Wolff C, Sutter RW, Aylward RB.

J Infect Dis. 2012 May 15;205(10):1554-61. doi: 10.1093/infdis/jis241. Epub 2012 Mar 23.

12.
13.

Polio control after certification: major issues outstanding.

Fine PE, Oblapenko G, Sutter RW.

Bull World Health Organ. 2004 Jan;82(1):47-52. Epub 2004 Feb 26.

14.

Mucosal immunity to poliovirus.

Ogra PL, Okayasu H, Czerkinsky C, Sutter RW.

Expert Rev Vaccines. 2011 Oct;10(10):1389-92. doi: 10.1586/erv.11.106.

PMID:
21988303
16.

Decision analysis in planning for a polio outbreak in the United States.

Jenkins PC, Modlin JF.

Pediatrics. 2006 Aug;118(2):611-8.

PMID:
16882814
17.

Strengths and weaknesses of current polio vaccines--a view from industry.

André FE.

Dev Biol (Basel). 2001;105:61-6.

PMID:
11763338
20.

The pathogenesis of poliomyelitis: what we don't know.

Nathanson N.

Adv Virus Res. 2008;71:1-50. doi: 10.1016/S0065-3527(08)00001-8. Review.

PMID:
18585526
Items per page

Supplemental Content

Write to the Help Desk